


Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
HDP-101 demonstrated complete response in one female patient…

Kaerus Bioscience’s lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS)
FDA’s two designations demonstrate KER-0193’s potential…

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025
– Proprietary manufacturing process enables robust and scalable…

Leucid Bio Announces Treatment of First Patient in AERIAL Trial of NKG2D CAR-T Therapy LEU011 for Solid Tumours
Initiation of AERIAL trial accelerated by successful first…

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia
Phase Ib/IIa trial is to evaluate the efficacy of VES001…

iOnctura commences randomized Phase I/II study in non-small cell lung cancer
First patient dosed in study investigating roginolisib + dostarlimab…

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
- New agreement with Lilly to license ATLX-1282, a first-in-class…

Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing
Agreement with Netherlands Center for the Clinical Advancement…

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
Phase I clinical results of DT-9081, an EP4 receptor antagonist,…

Novo Nordisk Foundation expands Challenge Programme outside of Denmark for the first time and significantly increases grants
Copenhagen, Denmark: The Novo Nordisk Foundation today announced…

Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding
Cycuria aims to revolutionise treatment of hard-to-treat…

Novo Holdings and EIFO invest €48 million in HealthCap IX to strengthen the Nordic life sciences ecosystem
Novo Holdings and the Export and Investment Fund of Denmark (EIFO)…

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma…

Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies
Significant market inefficiencies have left over USD$30 billion…

Astraveus Strengthens Leadership Team and Board
Jean-Paul Mangeolle joins as Chairman of the Board of Directors
…

Oxolife’s CEO Agnès Arbat receives prestigious EU Women Innovators Prize
Barcelona, Spain – 9 April 2025: Oxolife, the female fertility…

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
Revolutionary ‘off-the-shelf’ cancer vaccine designed…

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
Xeltis is one of only seven companies to successfully pass…

Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies
Copenhagen, Denmark – Novo Holdings today announced its financial…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York